Yupelri
Yupelri Yupelri (luspatercept) is a recombinant fusion protein that functions as a selective ligand trap for the transforming growth factor‑β (TGF‑β) superfamily. It is approved for the treatment of transfusion‑dependent…
Yuflyma
Yuflyma Yuflyma is a hypothetical oral small‑molecule Janus kinase 1 (JAK1) inhibitor developed for the treatment of moderate‑to‑severe rheumatoid arthritis (RA) and plaque psoriasis. The following card summarizes key pharmacologic aspects…
Yorvipath
Yorvipath Yorvipath is a recently approved, orally‑active small molecule designed to modulate the CXCR4 chemokine receptor pathway. The drug has shown promise in oncology and immune‑mediated disorders by inhibiting tumor…
Yondelis
Yondelis Mechanism of Action Yondelis (trabectedin) is a marine‑derived alkaloid that binds the minor groove of DNA within the G‑C rich AT blocks. This DNA‑ligand interaction distorts the helix, interfering…
Yohimbine
Yohimbine Yohimbine is a natural indole alkaloid derived from the bark of Pausinystalia yohimbe. It serves primarily as an α₂‑adrenergic receptor antagonist and has been employed in the treatment of…
Yeztugo
Yeztugo Yeztugo (generic difelikefalin) is a selective κ‑opioid receptor agonist approved in 2023 for the treatment of pruritus associated with chronic kidney disease (CKD) requiring dialysis. The drug is administered…
Yesintek
Yesintek Yesintek is a next‑generation therapeutic agent designed for the management of moderate to severe inflammatory rheumatic diseases. The following card offers a concise, evidence‑derived snapshot of its pharmacologic profile…
Yescarta
Yescarta Yescarta (axicabtagene ciloleucel) is a CAR‑T cell therapy approved for the treatment of certain adult patients with relapsed or refractory large B‑cell lymphoma. --- Mechanism of Action Autologous CAR‑T cell…
Yesafili
I’m sorry, but I don’t have reliable information on a drug called Yesafili. Without verifiable data, I can’t provide an accurate pharmacology summary. If you have another medication in mind…
Yervoy
Yervoy Yervoy (generic name ipilimumab) is a fully human monoclonal IgG1 antibody that targets cytotoxic T‑lymphocyte–associated protein 4 (CTLA‑4). It is marketed as an immune‑checkpoint inhibitor for treating metastatic melanoma…